56 research outputs found
A method for predicting the stability characteristics of an elastic airplane. Volume 4: FLEXSTAB 1.02.00 demonstration case and results
The polyamine spermine affects Ï-conotoxin binding and function at N-type voltage-sensitive calcium channels
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled crossâover trial
Abstract Aims Impaired myocardial energy homeostasis plays an import role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Left ventricular relaxation has a high energy demand, and left ventricular diastolic dysfunction has been related to impaired energy homeostasis. This study investigated whether trimetazidine, a fatty acid oxidation inhibitor, could improve myocardial energy homeostasis and consequently improve exercise haemodynamics in patients with HFpEF. Methods and results The DoPINGâHFpEF trial was a phase II singleâcentre, doubleâblind, placeboâcontrolled, randomized crossâover trial. Patients were randomized to trimetazidine treatment or placebo for 3Â months and switched after a 2âweek washâout period. The primary endpoint was change in pulmonary capillary wedge pressure, measured with right heart catheterization at multiple stages of bicycling exercise. Secondary endpoint was change in myocardial phosphocreatine/adenosine triphosphate, an index of the myocardial energy status, measured with phosphorusâ31 magnetic resonance spectroscopy. The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m2); with the diagnosis of HFpEF confirmed with (exercise) right heart catheterization either before or during the trial. There was no effect of trimetazidine on the primary outcome pulmonary capillary wedge pressure at multiple levels of exercise (mean change 0 [95% confidence interval, 95% CI â2, 2] mmHg over multiple levels of exercise, PÂ =Â 0.60). Myocardial phosphocreatine/adenosine triphosphate in the trimetazidine arm was similar to placebo (1.08 [0.76, 1.76] vs. 1.30 [0.95, 1.86], PÂ =Â 0.08). There was no change by trimetazidine compared with placebo in the exploratory parameters: 6âmin walking distance (mean change of â6 [95% CI â18, 7] m vs. â5 [95% CI â22, 22] m, respectively, PÂ =Â 0.93), Nâterminal proâBâtype natriuretic peptide (5 (â156, 166) ng/L vs. â13 (â172, 147) ng/L, PÂ =Â 0.70), overall qualityâofâlife (KCCQ and EQâ5Dâ5L, PÂ =Â 0.78 and PÂ =Â 0.51, respectively), parameters for diastolic function measured with echocardiography and cardiac magnetic resonance, or metabolic parameters. Conclusions Trimetazidine did not improve myocardial energy homeostasis and did not improve exercise haemodynamics in patients with HFpEF
Sulfonamide Antibiotics Embedded in High Silica Zeolite Y: A Combined Experimental and Theoretical Study of HostâGuest and GuestâGuest Interactions
Trace analysis of organics in aqueous samples by concentration in plastic tubing and multiplex gas chromatography
Measurement of hadron and lepton-pair production at 161 GeV<root s<172 GeV at LEP
Contains fulltext :
26256.pdf (publisher's version ) (Open Access
A Measurement of Pi-Polarization at Lep
Contains fulltext :
26223.pdf (publisher's version ) (Open Access
Automated Algorithm Selection on Continuous Black-Box Problems by Combining Exploratory Landscape Analysis and Machine Learning
- âŠ